Hang Yin (scientist)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Hang Hubert Yin
Born 5 July 1976 (1976-07-05) (age 42)
Alma mater Yale University
Scientific career
Fields Chemistry, Biology
Institutions Tsinghua University
Doctoral advisor Andrew D. Hamilton

Hang Hubert Yin (born 5 July 1976) is a professor of pharmaceutical sciences at Tsinghua University, a recipient of several young scientist awards for his research in chemical biology and drug discovery.

Career[edit]

Hang Hubert Yin was a pupil at the High School of Peking University. After studying for a bachelor's degree at the Peking University, he received his PhD from Yale University, New Haven in 2004 (supervisor: Professor Andrew D. Hamilton FRS) and then spent a post-doctoral period at the University of Pennsylvania School of Medicine under the supervision of Professor William DeGrado.[1] In 2007, he joined the faculty of the University of Colorado Boulder. His research interests lie at the interface of chemistry, biology, and engineering with particular focuses on structure-based drug design, cell signaling biochemistry, biotechnology development, and membrane protein simulations.[2]

Awards[edit]

Significant contributions[edit]

Yin's team showed that morphine causes inflammation by binding to the protein lymphocyte antigen 96, which, in turn, causes the protein to bind to an immune system receptor called Toll-like receptor 4 (TLR4).[11] The morphine-induced TLR4 activation attenuates pain suppression by opioid and enhances the development of opioid tolerance and addiction, drug abuse, and other negative side effects such as respiratory depression. The Yin group has developed drug candidates that can improve opioid-based pain management therapies.[12] On June 23, 2014, BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX) announced that it has in-licensed BL-1010, a novel compound for the treatment of neuropathic pain invented by Yin from the University of Colorado.[13] In 2015, Yin reported a new drug candidate that could change the way Parkinson's disease is treated.[14] The drug, called CU-CPT22, may help stop harmful inflammation in certain immune cells that is thought to cause Parkinson's.[15]

Notes[edit]

References[edit]

  1. ^ "Yin AACR Bio". Archived from the original on 2012-06-25.
  2. ^ "Yin Research Group Website".
  3. ^ "ACS MEDI".
  4. ^ "Chinese-American Chemistry Professor Association website".
  5. ^ "SU2C news coverage".
  6. ^ "University of Colorado Boulder news coverage".
  7. ^ "Elion Award lecture" (PDF).
  8. ^ "University of Colorado Technology Transfer Office news coverage". Archived from the original on 2012-12-10.
  9. ^ "University of Colorado Boulder news coverage".
  10. ^ "Howard Hughes Medical Institute news coverage".
  11. ^ Making morphine work better, Nature 2012, 484: 419
  12. ^ Drahl, C. Small Molecules Target Toll-Like Receptors, C&EN 2012, 90: 33
  13. ^ "BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain" (Press release). MarketWatch.
  14. ^ Making Aggregation Less Aggravating, Science 2015, 348: 769
  15. ^ "CU Parkinson's research could revolutionize treatment".